Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Climb Bio (CLYM) Capital Expenditures (2025)

Climb Bio filings provide 1 years of Capital Expenditures readings, the most recent being $109000.0 for Q3 2025.

Quarterly Capital Expenditures changed N/A to $109000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $109000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $186000.0 for FY2025, N/A changed from the prior year.
Capital Expenditures hit $109000.0 in Q3 2025 for Climb Bio.
Across five years, Capital Expenditures topped out at $109000.0 in Q3 2025 and bottomed at $109000.0 in Q3 2025.